Until today, Ozempic ® has not been available to eligible self-paying patients at this price SANTA MONICA, Calif. / Aug 18, 2025 / Business Wire / GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with Novo Nordisk , all strengths of Ozempic ® (semaglutide) and Wegovy ® (semaglutide) pens are available to eligible self-paying patients for $499-per-month... Read More